文献速递免疫规划传染病防控与疫情报告

PCV13对社区获得性肺炎血清型特异性疫苗效力的随机试验事后分析

A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
PubMed 文献 · Vaccine · 2019-05-31

该事后分析基于荷兰≥65岁人群的随机对照试验,评估PCV13对临床社区获得性肺炎(CAP)的血清型特异性疫苗效力(VE)。在272例临床CAP中,仅对对照组至少10例的5个血清型(1、3、6A、7F、19A)评估VE;血清型3和7F的VE有统计学意义。

要点

  • PCV13对血清型3临床CAP的VE为61.5%(95%CI 17.6–83.4%)。
  • PCV13对血清型7F临床CAP的VE为73.3%(95%CI 40.5–89.4%)。
  • 血清型1、6A、19A的VE点估计较低且置信区间包含0。

核心结论

  • 在≥65岁社区居住成人中,PCV13对血清型3和7F的临床CAP观察到统计学显著的VE。
  • 血清型1、6A、19A的VE点估计较低,但与其既往报告的总体VT-CAP VE 45.6%一致。

研究设计与样本

  • 社区获得性肺炎免疫试验(CAPITA)的事后分析,为平行臂随机临床试验。
  • 研究对象为荷兰≥65岁社区居住人群,评估13价肺炎球菌结合疫苗(PCV13)的VE。
  • 分析纳入符合临床CAP定义者,不论影像学结果;VT-CAP经培养或血清型特异性尿抗原检测(SSUAD)识别。
  • 仅纳入原始分析中对照组至少10例的5个血清型进行VE评估。

主要发现

  • 共272例临床CAP访视检出VT血清型,其中253例(93%)由SSUAD识别,210例(77%)仅由SSUAD识别。
  • 评估的血清型为1、3、6A、7F、19A,首次发作总数分别为27、36、25、38、48例。
  • 血清型1对首次临床CAP的VE为20.0%(95%CI -83.1%至65.8%)。
  • 血清型3的VE为61.5%(95%CI 17.6–83.4%)。
  • 血清型6A的VE为33.3%(95%CI -58.6%至73.2%)。

临床怎么用

  • 上述血清型特异性VE数据可用于模型,以更准确评估成人PCV13免疫规划的潜在影响。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serotype-specific vaccine efficacy (VE) against adult community acquired pneumonia (CAP) remains poorly defined, yet such data are important for assessing the utility of adult pneumococcal conjugate vaccine (PCV) programs. METHODS: We evaluated the Community Acquired Pneumonia Immunization Trial in Adults to assess serotype-specific VE for CAP. This parallel-arm randomized clinical trial assessed 13-valent PCV (PCV13) VE among community dwelling persons aged ≥65 years in The Netherlands. In the original analysis, PCV13 VE against first episodes of vaccine-type (VT) chest radiology confirmed CAP was 45.6% (95% confidence interval [CI] 21.8-62.5%). Unlike the original analysis, we included any subject that met a clinical definition of CAP regardless of radiographic findings. VT-CAP was identified by culture (sterile or non-sterile) or serotype-specific urinary antigen detection (SSUAD) test. Only the five serotypes with at least 10 episodes in the control arm, based on the original analysis, were included for VE assessment. RESULTS: Of 272 clinical CAP visits with VT serotypes identified, 253 (93%) were identified by SSUAD including 210 (77%) by SSUAD alone. VE was determined for serotypes 1, 3, 6A, 7F, and 19A, with total first episodes of, respectively, 27, 36, 25, 38, and 48. VE (95%CI) for the five evaluated serotypes against first clinical CAP episodes were: serotype 1, 20.0% (-83.1% to 65.8%); serotype 3, 61.5% (17.6-83.4%); serotype 6A, 33.3% (-58.6% to 73.2%); serotype 7F, 73.3% (40.5-89.4%); and serotype 19A, 45.2% (-2.2% to 71.5%). DISCUSSION: Statistically significant VE was observed for serotypes 3 and 7F for clinical CAP among elderly community dwelling adults. The VE point estimates and CIs for serotypes 1, 6A, and 19A were lower but consistent with the overall VT-CAP VE of 45.6% previously reported. These findings may be relevant in models to accurately account for the potential impact of adult PCV13 immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gessner BD, Jiang Q, Van Werkhoven CH, et al. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019. PMID: 31155413. doi:10.1016/j.vaccine.2019.05.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。